AI algorithm for detection of cardiac amyloidosis gains FDA breakthrough device status
Related Articles
Anumana expands AI cardiac care platform with support from Boston Scientific
MassDevice: Anumana announced today that it brought its diagnostic ECG-AI technology into perioperative and acute cardiac care with help from Boston Scientific.April 24, 2025
Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension
Mass Device: Anumana announced today that it received FDA breakthrough device designation for its pulmonary hypertension (PH) early detection algorithm. Cambridge, Massachusetts-based Anumana, formed by Mayo Clinic and nference and launched in…May 23, 2022
Pfizer partners with healthtech company on AI-powered cardiovascular disease detection
Becker's Hospital Review: Pharmaceutical giant Pfizer has partnered with digital health company Anumana, a company founded in 2021 in collaboration with the Mayo Clinic Platform, to develop an artificial intelligence…December 16, 2022
Pfizer links up with heart disease AI developer Anumana to build cardiac amyloidosis diagnostics
FIERCE Biotech: The heart-focused artificial intelligence company Anumana is looking to break new ground for its algorithms through a partnership with Pfizer. They plan to develop programs that can help…December 16, 2022